Literature DB >> 14735903

Frequent activation of AKT2 kinase in human pancreatic carcinomas.

Deborah A Altomare1, Satoshi Tanno, Assunta De Rienzo, Andres J Klein-Szanto, Sachie Tanno, Kristine L Skele, John P Hoffman, Joseph R Testa.   

Abstract

Activation of AKT/protein kinase B promotes a variety of biological activities important in tumorigenesis, such as cell survival and cell cycle progression. We previously demonstrated amplification and overexpression of the AKT2 gene in a subset of human pancreatic carcinomas. In this investigation, we assessed AKT2 catalytic activity in 50 frozen pancreatic tissues (37 carcinomas, four benign tumors and nine normal pancreata) by in vitro kinase assay. Twelve of 37 (32%) pancreatic carcinomas showed markedly elevated levels of AKT2 activity compared to normal pancreata and begin pancreatic tumors. To delineate mechanisms contributing to AKT2 activation in malignant pancreatic tumors, we examined the status of upstream components of the phosphatilydlinositol 3-kinase (PI3K)/AKT pathway. Western blot analysis revealed loss of PTEN protein expression in two of the 12 pancreatic carcinomas with activated AKT2. In vitro PI3K assays demonstrated high levels of PI3K activity in seven carcinoma specimens that showed AKT2 activation. Immunohistochemical staining confirmed high levels of phosphorylated (active) AKT in malignant pancreatic tumors compared to normal pancreata. Overall, these data suggest that upstream perturbations of the PI3K/AKT pathway contribute to frequent activation of AKT2 in pancreatic cancer, which may contribute to the pathogenesis of this highly aggressive form of human malignancy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14735903     DOI: 10.1002/jcb.10287

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  66 in total

1.  The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation.

Authors:  Claudia Nitsche; Mouad Edderkaoui; Ryan M Moore; Guido Eibl; Noriyuki Kasahara; Janet Treger; Paul J Grippo; Julia Mayerle; Markus M Lerch; Anna S Gukovskaya
Journal:  Gastroenterology       Date:  2011-10-29       Impact factor: 22.682

2.  RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells.

Authors:  Xin-Ke Zhou; Sheng-Song Tang; Gao Yi; Min Hou; Jin-Hui Chen; Bo Yang; Ji-Fang Liu; Zhi-Min He
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

3.  Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

Authors:  Kian Behbakht; Michael W Sill; Kathleen M Darcy; Stephen C Rubin; Robert S Mannel; Steven Waggoner; Russell J Schilder; Kathy Q Cai; Andrew K Godwin; R Katherine Alpaugh
Journal:  Gynecol Oncol       Date:  2011-07-12       Impact factor: 5.482

Review 4.  Biology and management of pancreatic cancer.

Authors:  Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

5.  Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90.

Authors:  Yanyan Li; G Elif Karagöz; Young Ho Seo; Tao Zhang; Yiqun Jiang; Yanke Yu; Afonso M S Duarte; Steven J Schwartz; Rolf Boelens; Kate Carroll; Stefan G D Rüdiger; Duxin Sun
Journal:  J Nutr Biochem       Date:  2012-03-23       Impact factor: 6.048

6.  Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma.

Authors:  Olga K Mirzoeva; Byron Hann; Yun K Hom; Jayanta Debnath; Dana Aftab; Kevan Shokat; W Michael Korn
Journal:  J Mol Med (Berl)       Date:  2011-06-16       Impact factor: 4.599

Review 7.  Exploiting novel molecular targets in gastrointestinal cancers.

Authors:  Wen W Ma; Manuel Hidalgo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis.

Authors:  Piotr G Rychahou; JungHee Kang; Pat Gulhati; Hung Q Doan; L Andy Chen; Shu-Yuan Xiao; Dai H Chung; B Mark Evers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

Review 9.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

10.  MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2.

Authors:  Niamh H Foley; Isabella M Bray; Amanda Tivnan; Kenneth Bryan; Derek M Murphy; Patrick G Buckley; Jacqueline Ryan; Anne O'Meara; Maureen O'Sullivan; Raymond L Stallings
Journal:  Mol Cancer       Date:  2010-04-21       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.